Johnson Investment Counsel Inc. Has $3.08 Million Stock Position in Option Care Health, Inc. $OPCH

Johnson Investment Counsel Inc. grew its holdings in shares of Option Care Health, Inc. (NASDAQ:OPCH) by 25.5% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 110,992 shares of the company’s stock after purchasing an additional 22,536 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in Option Care Health were worth $3,081,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Durable Capital Partners LP increased its position in Option Care Health by 134.2% during the second quarter. Durable Capital Partners LP now owns 8,237,577 shares of the company’s stock worth $267,557,000 after buying an additional 4,720,988 shares during the last quarter. Norges Bank bought a new stake in shares of Option Care Health during the 2nd quarter worth about $69,932,000. Swedbank AB acquired a new position in shares of Option Care Health during the 3rd quarter valued at about $49,455,000. Arrowstreet Capital Limited Partnership raised its stake in shares of Option Care Health by 109.0% in the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 3,410,394 shares of the company’s stock valued at $110,770,000 after acquiring an additional 1,778,279 shares in the last quarter. Finally, Jennison Associates LLC raised its stake in shares of Option Care Health by 145.6% in the 2nd quarter. Jennison Associates LLC now owns 2,138,248 shares of the company’s stock valued at $69,450,000 after acquiring an additional 1,267,660 shares in the last quarter. Institutional investors and hedge funds own 98.05% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Stephens raised Option Care Health to a “strong-buy” rating in a research report on Thursday, December 11th. Wall Street Zen raised shares of Option Care Health from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Deutsche Bank Aktiengesellschaft raised their target price on shares of Option Care Health from $31.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Jefferies Financial Group reissued a “buy” rating and set a $37.00 target price on shares of Option Care Health in a research report on Tuesday, January 13th. Finally, National Bankshares set a $37.00 price target on Option Care Health in a research report on Tuesday, January 27th. One research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat, Option Care Health currently has a consensus rating of “Moderate Buy” and an average price target of $37.46.

Option Care Health Price Performance

NASDAQ:OPCH opened at $33.15 on Wednesday. The company has a debt-to-equity ratio of 0.85, a current ratio of 1.56 and a quick ratio of 1.05. Option Care Health, Inc. has a one year low of $24.24 and a one year high of $36.80. The company has a fifty day moving average price of $33.32 and a 200 day moving average price of $30.06. The stock has a market cap of $5.26 billion, a P/E ratio of 26.31, a PEG ratio of 1.98 and a beta of 0.84.

Option Care Health Company Profile

Option Care Health (NASDAQ: OPCH) is a leading provider of home and alternate site infusion services in the United States. The company specializes in the administration of injectable therapies, including antibiotics, nutrition, hydration, immunoglobulin, pain management and specialty pharmaceuticals. Through its nationwide network of infusion pharmacies and nursing professionals, Option Care Health delivers customized care plans and in-home nursing visits to patients managing complex or chronic conditions outside of a hospital setting.

Option Care Health traces its current structure to the completion of its merger with BioScrip in early 2021, combining two of the industry’s most experienced home infusion businesses.